Crispr Therapeutics AG vs Grab Holdings Ltd. — how do they compare? Crispr Therapeutics AG trades at $53.88 (market cap $5.17B), while Grab Holdings Ltd. trades at $3.74 (market cap $14.97B). The key difference: Grab Holdings Ltd. is far larger — about 2.9× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| CRSP | GRAB | |
|---|---|---|
Market Cap | $5.17B | $14.97B |
Sector | Health | Technology |
52-Week High | $76.78 | $6.45 |
52-Week Low | $44.34 | $3.27 |
Enterprise Value | $3.59B | $10.70B |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →